Gastrointestinal cancer research : GCR最新文献_第10页

A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. 西妥昔单抗联合吉西他滨和放疗治疗局部晚期胰腺癌的I期研究。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

A Bapsi Chakravarthy, Chiao Jillian Tsai, Nathan O'Brien, A Craig Lockhart, Emily Chan, Alexander Parikh, Jordan D Berlin, Nipun Merchant

{"title":"A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer.","authors":"A Bapsi Chakravarthy, Chiao Jillian Tsai, Nathan O'Brien, A Craig Lockhart, Emily Chan, Alexander Parikh, Jordan D Berlin, Nipun Merchant","doi":"","DOIUrl":"","url":null,"abstract":"Background: Cetuximab is a monoclonal antibody against the epidermal growth factor receptor (EGFR). The primary goal of this phase I study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of gemcitabine when combined with cetuximab plus radiation in patients with locally advanced pancreatic cancer.Patients and methods: Patients with locally unresectable adenocarcinoma of the pancreas were treated with gemcitabine (200 mg/m(2)/week before dose escalation) plus cetuximab (400 mg/m(2) loading dose, 250 mg/m(2) weekly maintenance dose) concurrent with radiation (50.4 Gy).Results: Nine patients were enrolled in the study. One withdrew due to declining performance status before receiving any therapy. Grade 4 allergic reactions to cetuximab caused the withdrawal of 2 patients. Another patient had elevated liver function test results and a stroke after his loading dose of cetuximab. Grade 3 or 4 toxicity developed in 3 of the remaining 5 patients treated with the level 1 dose. Therefore, no further dose escalations were planned. Grade 3 toxicities included nausea, vomiting, ileus, and pneumonitis. One patient had grade 4 diarrhea.Conclusions: The combination of cetuximab, gemcitabine, and radiation resulted in significant toxicity. A recommended phase II dose could not be determined.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433259/pdf/gcr112.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30986322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastric Adenocarcinoma in the Duodenal Stump 40 Years After a Billroth II Partial Gastrectomy for Benign Indications. 良性胃部分切除40年后十二指肠残端发生胃腺癌。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

Jessica F Rose, Lenka Stankova, Evan S Glazer, Hugo V Villar

引用次数: 0

Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer. 直肠癌化疗期间患者报告结果与临床医生报告症状的对比。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

Libertad T Flores, Antonia V Bennett, Ethel B Law, Carla Hajj, Mindy P Griffith, Karyn A Goodman

{"title":"Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer.","authors":"Libertad T Flores, Antonia V Bennett, Ethel B Law, Carla Hajj, Mindy P Griffith, Karyn A Goodman","doi":"","DOIUrl":"","url":null,"abstract":"Background: Pelvic radiotherapy with concurrent 5-fluorouracil-based chemotherapy is a component of standard therapy for patients with T3/T4 or node-positive rectal cancer and may be associated with acute gastrointestinal toxicity. In this retrospective study, we sought to compare patient-reported outcomes (PROs) with clinician reports of acute symptoms experienced by rectal cancer patients receiving chemoradiation.Patients and methods: Charts of 199 patients with rectal cancer who received chemoradiation at some point from November 2006 through February 2011 were reviewed. Clinicians assessed toxicity weekly using Common Terminology for Clinical Adverse Events version 3.0, and, beginning in September 2009, the patients reported symptoms weekly, using the 7-item Bowel Problems Scale. One hundred ninety-seven patients with at least 1 clinician or patient assessment were eligible for the study. We used descriptive statistics to compare patient and clinician assessments in a subgroup of 65 patients (paired group) who had at least 1 patient and clinician assessment on the same day. Cohen's κ coefficient was used to evaluate agreement between the patients and the clinicians.Results: The patients reported diarrhea and proctitis more often than clinicians reported them throughout treatment. Uncorrected agreement for diarrhea and proctitis was 82% and 72%, respectively. Cohen's κ was .64 for diarrhea, indicating moderate agreement, and .22 for proctitis, indicating only slight agreement.Conclusions: Our findings suggest a discrepancy between clinician and PRO reports. Further study may discern potential benefits of collecting PROs in prospective studies and in clinical practice.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433260/pdf/gcr119.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30986323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2011 update in gastrointestinal cancer therapeutics. 2011 年胃肠癌疗法的最新进展。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

Vaibhav Sahai, Halla Nimeiri, Al B Benson

引用次数: 0

Round ligament metastatic gastric cancer as a finding in an inguinal surgery. 腹股沟手术发现圆形韧带转移性胃癌。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

Ana Ruiz-Casado, Carlos Miliani, Cristina López, Montserrat López, Teresa Martin, Fernando Pereira

引用次数: 0

Upcoming articles. 即将到来的文章。

Gastrointestinal cancer research : GCR Pub Date : 2012-07-01

引用次数: 0

Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. 奥曲肽- lar在转移性小肠类癌患者中的应用

Gastrointestinal cancer research : GCR Pub Date : 2012-05-20 DOI: 10.1200/JCO.2012.30.15_SUPPL.E14579

J. Strosberg, J. Weber, M. Feldman, J. Goldman, K. Almhanna, L. Kvols

{"title":"Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.","authors":"J. Strosberg, J. Weber, M. Feldman, J. Goldman, K. Almhanna, L. Kvols","doi":"10.1200/JCO.2012.30.15_SUPPL.E14579","DOIUrl":"https://doi.org/10.1200/JCO.2012.30.15_SUPPL.E14579","url":null,"abstract":"BACKGROUND\u0000Octreotide LAR is indicated for treatment of malignant carcinoid syndrome and has been studied at doses of 10 to 30 mg intramuscularly every 4 weeks. In clinical practice, higher doses are often prescribed for patients who experience refractory carcinoid syndrome (flushing and/or diarrhea) or tumor growth while on the maximum label-recommended dose.\u0000\u0000\u0000METHODS\u0000We performed a retrospective, longitudinal review of octreotide LAR administration at a tertiary institution to determine the frequency of above-label dosing and outcomes.\u0000\u0000\u0000RESULTS\u0000Three hundred thirty-eight patients were considered evaluable, among whom 100 (30%) underwent at least 1 increase in dose or frequency of octreotide-LAR above the standard label dose. The most common maximum doses were 40 mg every 4 weeks (n = 37 patients), 60 mg every 4 weeks (n = 34), and 30 mg every 3 weeks (n = 18). The indications for dose increase were worsening carcinoid syndrome (n = 60), radiographic progression (n = 33), and rising urine 5-HIAA (n = 6). Of the patients whose doses were increased for refractory carcinoid syndrome, 62% (n = 34) experienced improvement in diarrhea, and 56% (n = 28) experienced improvement in flushing.\u0000\u0000\u0000CONCLUSIONS\u0000In conclusion, octreotide LAR is commonly prescribed in doses or schedules above the recommended dose and frequency. Patients with refractory carcinoid syndrome appear to experience a clinical benefit from this change. Prospective data may be used to further evaluate this strategy.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76261295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39

A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. 甲磺酸伊马替尼和吉西他滨一线治疗晚期胰腺癌的多机构2期研究

Gastrointestinal cancer research : GCR Pub Date : 2012-05-01

Rebecca A Moss, Dirk Moore, Mary F Mulcahy, Kenneth Nahum, Biren Saraiya, Simantini Eddy, Martin Kleber, Elizabeth A Poplin

{"title":"A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer.","authors":"Rebecca A Moss, Dirk Moore, Mary F Mulcahy, Kenneth Nahum, Biren Saraiya, Simantini Eddy, Martin Kleber, Elizabeth A Poplin","doi":"","DOIUrl":"","url":null,"abstract":"Background: The pancreatic tumor microenvironment is rich in receptors for platelet-derived growth factor (PDGFRs). Imatinib mesylate (IM) inhibits PDGFRs and decreases tumor interstitial fluid pressure, potentially improving drug access. These data and promising results in a phase 1 trial formed the rationale for a phase 2 trial combining IM and gemcitabine (GEM) in pancreatic cancer.Methods: Eligibility criteria included chemotherapy-naïve, locally advanced or metastatic pancreatic cancer; ECOG (Eastern Cooperative Oncology Group) performance status ≤2; and adequate end-organ function. The primary end point was progression-free survival (PFS). Secondary end points included response rate, toxicity, and overall survival (OS). GEM was given at 1200 mg/m(2)/120 min on days 3 and 10. IM (400 mg) was taken orally on days 1 to 5 and 8 to 12 of a 21-day cycle. Response was assessed every 3 cycles.Results: Forty-four patients from 7 centers were enrolled from October 2005 through July 2009. Median age was 62 years. The median number of cycles completed was 3 (range, 0-17). Common adverse effects included neutropenia, nausea, anemia, and fatigue. Half the patients required dose reductions. There were no complete responses to therapy. During treatment, 1 patient showed a partial response, 16 had stable disease, and 18 had progressive disease. The median PFS was 3.9 months (95% confidence interval, 2.1-5.1), the median OS was 6.3 months (95% confidence interval, 5.2-8.5), and the 1-year survival rate was 25.6% (95% confidence interval, 13.8-39.1).Conclusion: IM in combination with GEM is tolerated in locally advanced, metastatic, or recurrent pancreatic cancer, but does not show a statistically significant PFS or OS benefit over chemotherapy with GEM alone.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415717/pdf/gcr77.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30830281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trastuzumab for a patient with heavily pretreated gastric cancer plus massive ascites and ovarian metastasis. 曲妥珠单抗用于重度预处理胃癌合并大量腹水和卵巢转移的患者。

Gastrointestinal cancer research : GCR Pub Date : 2012-05-01

Kohei Shitara, Yasushi Yatabe, Tomoya Yokota, Daisuke Takahari, Takashi Shibata, Takashi Ura, Yozo Satoh, Yasuhiro Kodera, Kei Muro

引用次数: 0

What's New in Transarterial Therapies for Hepatocellular Carcinoma? 肝细胞癌经动脉治疗的新进展?

Gastrointestinal cancer research : GCR Pub Date : 2012-05-01

Benjamin J May, Ravi Murthy, David C Madoff

引用次数: 0